Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes
JAMA
.
2016 Oct 4;316(13):1407-1408.
doi: 10.1001/jama.2016.11708.
Authors
Richard M Bergenstal
1
,
Satish Garg
2
,
Stuart A Weinzimer
3
,
Bruce A Buckingham
4
,
Bruce W Bode
5
,
William V Tamborlane
3
,
Francine R Kaufman
6
Affiliations
1
International Diabetes Center, Minneapolis, Minnesota.
2
Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora.
3
Yale University, New Haven, Connecticut.
4
Stanford University, Stanford, California.
5
Atlanta Diabetes Associates, Atlanta, Georgia.
6
Medtronic, Northridge, California.
PMID:
27629148
DOI:
10.1001/jama.2016.11708
No abstract available
Publication types
Comment
MeSH terms
Algorithms
Blood Glucose
Diabetes Mellitus, Type 1 / drug therapy*
Humans
Hypoglycemic Agents / therapeutic use
Insulin / therapeutic use*
Insulin Infusion Systems
Substances
Blood Glucose
Hypoglycemic Agents
Insulin